Finally, the signature derived from cluster2 KLRC1+ KLRK1+TRM CD28− (Fig. 7D,F and Table S4), likely characterized by a TRM phenotype and expressed in both NT and tumor site (C2 KLRC1+ KLRK1+TRM CD28− /Adaptive immunity) and including KLRC1, CD8A, CD8B, CD3E, KLRK1, was not significantly prognostic in all patient subgroups in the LUAD TCGA dataset (Fig. 8E). Here, CD8A is linked to neoplasm.